Financial Overview - Vir Biotechnology had $810.7 million in cash and investments as of September 30, 2025, providing a cash runway into mid-2027[11] - Q3 2025 total revenues were $0.2 million, a 92% decrease from $2.4 million in Q3 2024[134] - Research and development expenses for Q3 2025 were $151.5 million, a 22% decrease from $195.2 million in Q3 2024[134] - Net loss for Q3 2025 was $(163.1) million, compared to $(213.7) million in Q3 2024, a 24% improvement[134] Hepatitis Delta Program (Tobevibart + Elebsiran) - In an ongoing Phase 2 trial, 41% of participants achieved HDV RNA <Target Not Detected (0 IU/mL) at 24 weeks, and 64% at 36 weeks with tobevibart + elebsiran Q4W de novo[31] - 90% of participants receiving tobevibart + elebsiran achieved HBsAg <10 IU/mL, compared to only 22% with tobevibart monotherapy Q2W at Week 24[36] - ECLIPSE 1, a Phase 3 trial for Hepatitis Delta, is fully enrolled, with topline data for all three ECLIPSE studies expected in Q1 2027[40] Oncology - PRO-XTEN® Masked TCE Platform - VIR-5500 (PSMA): In Phase 1 testing, 58% of patients with 1st dose ≥ 120 µg/kg showed PSA50 responses[66] - VIR-5818 (HER2): In heavily pre-treated CRC patients (≥400 µg/kg), a 33% response rate was observed[118] - VIR-5818 (HER2): ctDNA Molecular response in 54% of subjects[118] - VIR-5525 (EGFR): Phase 1 study initiated in Q3 2025, targeting NSCLC, CRC, HNSCC, and cSCC[51]